{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:33:33Z","timestamp":1790393613119,"version":"4.1.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s12032-020-01416-3","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T18:03:07Z","timestamp":1602525787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"37","author":[{"given":"Mohadese","family":"Hashem Boroojerdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0890-8366","authenticated-orcid":false,"given":"Fatemeh","family":"Rahbarizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouya","family":"Safarzadeh Kozani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elahe","family":"Kamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooria","family":"Safarzadeh Kozani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"issue":"15","key":"1416_CR1","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1200\/jco.2009.27.0421","volume":"28","author":"MA Smith","year":"2010","unstructured":"Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010;28(15):2625\u201334. https:\/\/doi.org\/10.1200\/jco.2009.27.0421.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1416_CR2","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015;373(16):1541\u201352. https:\/\/doi.org\/10.1056\/NEJMra1400972.","journal-title":"N Engl J Med"},{"issue":"5","key":"1416_CR3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cmet.2015.10.005","volume":"22","author":"B Knoechel","year":"2015","unstructured":"Knoechel B, Aster JC. Metabolic mechanisms of drug resistance in leukemia. Cell Metab. 2015;22(5):759\u201360.","journal-title":"Cell Metab"},{"issue":"4","key":"1416_CR4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450\u201361.","journal-title":"Cancer Cell"},{"issue":"15","key":"1416_CR5","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2005.09.117","volume":"23","author":"F Aversa","year":"2005","unstructured":"Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23(15):3447\u2013544.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1416_CR6","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1002\/jcp.26049","volume":"233","author":"M Mashreghi","year":"2018","unstructured":"Mashreghi M, Azarpara H, Bazaz MR, Jafari A, Masoudifar A, Mirzaei H, et al. Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis. J Cell Physiol. 2018;233(4):2949\u201365.","journal-title":"J Cell Physiol"},{"issue":"15","key":"1416_CR7","doi-asserted-by":"publisher","first-page":"7008","DOI":"10.1200\/JCO.2017.35.15_suppl.7008","volume":"35","author":"JH Park","year":"2017","unstructured":"Park JH, Riviere I, Wang X, Senechal B, Wang Y, Mead E, et al. Durable long-term survival of adult patients with relapsed B-ALL after CD19 CAR (19\u201328z) T-cell therapy. J Clini Oncol. 2017;35(15):7008. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.7008.","journal-title":"J Clini Oncol"},{"issue":"16","key":"1416_CR8","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317.","journal-title":"N Engl J Med"},{"issue":"15","key":"1416_CR9","doi-asserted-by":"publisher","first-page":"7010","DOI":"10.1200\/jco.2015.33.15_suppl.7010","volume":"33","author":"JH Park","year":"2015","unstructured":"Park JH, Riviere I, Wang X, Bernal Y, Purdon T, Halton E, et al. Efficacy and safety of CD19-targeted 19\u201328z CAR modified T cells in adult patients with relapsed or refractory B-ALL. J Clin Oncol. 2015;33(15):7010\u20137010. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.7010.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1416_CR10","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","volume":"14","author":"SJ Van Der Stegen","year":"2015","unstructured":"Van Der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discovery. 2015;14(7):499\u2013509.","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"1416_CR11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics. A Cancer J Clinic. 2015;65(1):5\u201329.","journal-title":"A Cancer J Clinic"},{"issue":"2","key":"1416_CR12","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","volume":"354","author":"C-H Pui","year":"2006","unstructured":"Pui C-H, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166\u201378.","journal-title":"N Engl J Med"},{"issue":"26","key":"1416_CR13","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017\u201323.","journal-title":"Blood"},{"issue":"1","key":"1416_CR14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/bjh.14475","volume":"177","author":"RJ Orlowski","year":"2017","unstructured":"Orlowski RJ, Porter DL, Frey NV. The promise of chimeric antigen receptor T cells (CART s) in leukaemia. Br J Haematol. 2017;177(1):13\u201326.","journal-title":"Br J Haematol"},{"key":"1416_CR15","unstructured":"Feinberg BA, Fillman J, Simoncini J, Nabhan C. CAR-T cells: the next era in immuno-oncology. Am J Manag Care. 2017;23(2 Spec No.):Sp48-sp52."},{"issue":"11","key":"1416_CR16","doi-asserted-by":"crossref","first-page":"e1046673","DOI":"10.1080\/2162402X.2015.1046673","volume":"4","author":"F Aranda","year":"2015","unstructured":"Aranda F, Buqu\u00e9 A, Bloy N, Castoldi F, Eggermont A, Cremer I, et al. Trial Watch: Adoptive cell transfer for oncological indications. Oncoimmunology. 2015;4(11):e1046673.","journal-title":"Oncoimmunology"},{"issue":"4","key":"1416_CR17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11427-016-5034-5","volume":"59","author":"C Luo","year":"2016","unstructured":"Luo C, Wei J, Han W. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China. Science China Life Sciences. 2016;59(4):349\u201359.","journal-title":"Science China Life Sciences"},{"issue":"2","key":"1416_CR18","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/2326-6066.CIR-14-0163","volume":"3","author":"C Berger","year":"2015","unstructured":"Berger C, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A, Paszkiewicz PJ, et al. Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor-Modified T Cells. Cancer Immunol Res. 2015;3(2):206\u201316.","journal-title":"Cancer Immunol Res"},{"issue":"13","key":"1416_CR19","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","volume":"24","author":"CH Lamers","year":"2006","unstructured":"Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006;24(13):e20\u2013e2222.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1416_CR20","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","volume":"123","author":"MV Maus","year":"2014","unstructured":"Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014;123(17):2625\u201335.","journal-title":"Blood"},{"issue":"7","key":"1416_CR21","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ctrv.2010.03.004","volume":"36","author":"A Deol","year":"2010","unstructured":"Deol A, Lum LG. Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev. 2010;36(7):528\u201338.","journal-title":"Cancer Treat Rev"},{"key":"1416_CR22","doi-asserted-by":"publisher","first-page":"5474602","DOI":"10.1155\/2016\/5474602","volume":"2016","author":"H Alm\u00e5sbak","year":"2016","unstructured":"Alm\u00e5sbak H, Aarvak T, Vemuri MC. CAR T Cell Therapy: A Game Changer in Cancer Treatment. J Immunol Res. 2016;2016:5474602. https:\/\/doi.org\/10.1155\/2016\/5474602.","journal-title":"J Immunol Res"},{"issue":"23","key":"1416_CR23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1182\/blood.V126.23.184.184","volume":"126","author":"CJ Turtle","year":"2015","unstructured":"Turtle CJ, Berger C, Sommermeyer D, Hanafi L-A, Pender B, Robinson EM, et al. Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes. Blood. 2015;126(23):184\u20131844. https:\/\/doi.org\/10.1182\/blood.V126.23.184.184.","journal-title":"Blood"},{"issue":"6","key":"1416_CR24","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/PPO.0000000000000158","volume":"21","author":"C Yee","year":"2015","unstructured":"Yee C, Lizee G, Schueneman AJ. Endogenous T-cell therapy: clinical experience. The Cancer Journal. 2015;21(6):492\u2013500.","journal-title":"The Cancer Journal"},{"issue":"9","key":"1416_CR25","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","volume":"127","author":"JA Fraietta","year":"2016","unstructured":"Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127(9):1117\u201327.","journal-title":"Blood"},{"issue":"9967","key":"1416_CR26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. The Lancet. 2015;385(9967):517\u201328.","journal-title":"The Lancet"},{"issue":"374","key":"1416_CR27","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1126\/scitranslmed.aaj2013","volume":"9","author":"W Qasim","year":"2017","unstructured":"Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017;9(374):2013. https:\/\/doi.org\/10.1126\/scitranslmed.aaj2013.","journal-title":"Sci Transl Med"},{"issue":"6","key":"1416_CR28","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2014","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2014;33(6):540\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1416_CR29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.retram.2017.08.003","volume":"65","author":"J Gauthier","year":"2017","unstructured":"Gauthier J, Yakoub-Agha I. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: clinical data to date, current limitations and perspectives. Current Research in Translational Medicine. 2017;65(3):93\u2013102.","journal-title":"Current Research in Translational Medicine"},{"issue":"6","key":"1416_CR30","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/cas.13239","volume":"108","author":"S Makita","year":"2017","unstructured":"Makita S, Yoshimura K, Tobinai K. Clinical development of anti-CD 19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Sci. 2017;108(6):1109\u201318.","journal-title":"Cancer Sci"},{"issue":"18","key":"1416_CR31","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens RJ, Rivi\u00e8re I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817\u201328.","journal-title":"Blood"},{"issue":"224","key":"1416_CR32","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and Toxicity Management of 19\u201328z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. Science Translational Medicine. 2014;6(224):224ra25\u2013ra25. https:\/\/doi.org\/10.1126\/scitranslmed.3008226.","journal-title":"Science Translational Medicine."},{"issue":"15","key":"1416_CR33","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/jco.2015.33.15_suppl.3007","volume":"33","author":"GL Beatty","year":"2015","unstructured":"Beatty GL, O'Hara MH, Nelson AM, McGarvey M, Torigian DA, Lacey SF, et al. Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer. J Clin Oncol. 2015;33(15):3007\u20133007. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.3007.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1416_CR34","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188\u201395.","journal-title":"Blood"},{"issue":"16","key":"1416_CR35","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509\u201318.","journal-title":"N Engl J Med"},{"issue":"17","key":"1416_CR36","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","volume":"122","author":"CRY Cruz","year":"2013","unstructured":"Cruz CRY, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;122(17):2965\u201373.","journal-title":"Blood"},{"issue":"18","key":"1416_CR37","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.yexcr.2011.08.015","volume":"317","author":"FJ Iri-Sofla","year":"2011","unstructured":"Iri-Sofla FJ, Rahbarizadeh F, Ahmadvand D, Rasaee MJ. Nanobody-based chimeric receptor gene integration in Jurkat cells mediated by PhiC31 integrase. Exp Cell Res. 2011;317(18):2630\u201341.","journal-title":"Exp Cell Res"},{"issue":"1","key":"1416_CR38","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.bbagen.2013.09.029","volume":"1840","author":"FR Jamnani","year":"2014","unstructured":"Jamnani FR, Rahbarizadeh F, Shokrgozar MA, Mahboudi F, Ahmadvand D, Sharifzadeh Z, et al. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy. Biochim Biophys Acta. 2014;1840(1):378\u201386. https:\/\/doi.org\/10.1016\/j.bbagen.2013.09.029.","journal-title":"Biochim Biophys Acta"},{"issue":"5\u20136","key":"1416_CR39","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","volume":"18","author":"R Scheuermann","year":"1995","unstructured":"Scheuermann R, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leukemia & lymphoma. 1995;18(5\u20136):385\u201397.","journal-title":"Leukemia & lymphoma"},{"issue":"1","key":"1416_CR40","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1073\/pnas.0911726107","volume":"107","author":"A Yoda","year":"2010","unstructured":"Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci. 2010;107(1):252\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"9","key":"1416_CR41","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.4049\/jimmunol.1400864","volume":"193","author":"EL Kuan","year":"2014","unstructured":"Kuan EL, Ziegler SF. Thymic stromal lymphopoietin and cancer. J Immunol. 2014;193(9):4283\u20138.","journal-title":"J Immunol"},{"issue":"5","key":"1416_CR42","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood-2014-11-612903","volume":"126","author":"H Qin","year":"2015","unstructured":"Qin H, Cho M, Haso W, Zhang L, Tasian SK, Oo HZ, et al. Eradication of B-ALL using chimeric antigen receptor\u2013expressing T cells targeting the TSLPR oncoprotein. Blood. 2015;126(5):629\u201339.","journal-title":"Blood"},{"issue":"23","key":"1416_CR43","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1182\/blood.V126.23.1324.1324","volume":"126","author":"TJ Fry","year":"2015","unstructured":"Fry TJ, Stetler-Stevenson M, Shah NN, Yuan CM, Yates B, Delbrook C, et al. Clinical Activity and Persistence of Anti-CD22 Chimeric Antigen Receptor in Children and Young Adults with Relapsed\/Refractory Acute Lymphoblastic Leukemia (ALL). Blood. 2015;126(23):1324\u20131324. https:\/\/doi.org\/10.1182\/blood.V126.23.1324.1324.","journal-title":"Blood"},{"issue":"15","key":"1416_CR44","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1200\/jco.2015.33.15_suppl.3006","volume":"33","author":"CJ Turtle","year":"2015","unstructured":"Turtle CJ, Berger C, Sommermeyer D, Budiarto T, Hanafi L-A, Melville K, et al. Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition. J Clin Oncol. 2015;33(15):3006\u20133006. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.3006.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1416_CR45","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1182\/blood.V124.21.311.311","volume":"124","author":"P Kebriaei","year":"2014","unstructured":"Kebriaei P, Huls H, Singh H, Olivares S, Figliola M, Maiti S, et al. Adoptive Therapy Using Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells to Manufacture T Cells Expressing CD19-Specific Chimeric Antigen Receptor. Blood. 2014;124(21):311\u2013311. https:\/\/doi.org\/10.1182\/blood.V124.21.311.311.","journal-title":"Blood"},{"issue":"21","key":"1416_CR46","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1182\/blood.V124.21.380.380","volume":"124","author":"SA Grupp","year":"2014","unstructured":"Grupp SA, Maude SL, Shaw P, Aplenc R, Barrett DM, Callahan C, et al. T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed. Refractory ALL. Blood. 2014;124(21):380\u2013380. https:\/\/doi.org\/10.1182\/blood.V124.21.380.380.","journal-title":"Refractory ALL. Blood"},{"issue":"2","key":"1416_CR47","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2012.08.010","volume":"334","author":"Z Sharifzadeh","year":"2013","unstructured":"Sharifzadeh Z, Rahbarizadeh F, Shokrgozar MA, Ahmadvand D, Mahboudi F, Jamnani FR, et al. Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents. Cancer Lett. 2013;334(2):237\u201344.","journal-title":"Cancer Lett"},{"issue":"3","key":"1416_CR48","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147\u201367. https:\/\/doi.org\/10.1038\/s41571-019-0297-y.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1416_CR49","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor\u2013modified T cells in lymphoma patients. J Clin Investig. 2011;121(5):1822.","journal-title":"J Clin Investig"},{"issue":"8","key":"1416_CR50","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nri1148","volume":"3","author":"M Croft","year":"2003","unstructured":"Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol. 2003;3(8):609\u201320.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"1416_CR51","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.hoc.2013.01.003","volume":"27","author":"JC Riches","year":"2013","unstructured":"Riches JC, Gribben JG. Understanding the Immunodeficiency in Chronic Lymphocytic Leukemia: Potential Clinical Implications. Hematology\/Oncology Clinics. 2013;27(2):207\u201335. https:\/\/doi.org\/10.1016\/j.hoc.2013.01.003.","journal-title":"Hematology\/Oncology Clinics"},{"issue":"12","key":"1416_CR52","doi-asserted-by":"crossref","first-page":"e0144787","DOI":"10.1371\/journal.pone.0144787","volume":"10","author":"H Karlsson","year":"2015","unstructured":"Karlsson H, Svensson E, Gigg C, Jarvius M, Olsson-Str\u00f6mberg U, Savoldo B, et al. Evaluation of intracellular signaling downstream chimeric antigen receptors. PLoS ONE. 2015;10(12):e0144787.","journal-title":"PLoS ONE"},{"issue":"17","key":"1416_CR53","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","volume":"119","author":"BG Till","year":"2012","unstructured":"Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4\u20131BB domains: pilot clinical trial results. Blood. 2012;119(17):3940\u201350. https:\/\/doi.org\/10.1182\/blood-2011-10-387969.","journal-title":"Blood"},{"issue":"9","key":"1416_CR54","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0813101106","volume":"106","author":"C Carpenito","year":"2009","unstructured":"Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009;106(9):3360\u20135. https:\/\/doi.org\/10.1073\/pnas.0813101106.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1416_CR55","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4\u20131BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581\u201390. https:\/\/doi.org\/10.1038\/nm.3838.","journal-title":"Nat Med"},{"key":"1416_CR56","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000437180","volume":"42","author":"M Pircher","year":"2015","unstructured":"Pircher M, Schirrmann T, Petrausch U. T Cell Engineering Prog Tumor Res. 2015;42:110\u201335. https:\/\/doi.org\/10.1159\/000437180.","journal-title":"T Cell Engineering Prog Tumor Res"},{"issue":"4","key":"1416_CR57","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Condomines M, van der Stegen SJ, Perna F, Kloss CC, Gunset G, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 2015;28(4):415\u201328.","journal-title":"Cancer Cell"},{"issue":"3","key":"1416_CR58","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, Fraietta JA, Guo L, McGettigan SE, Posey AD, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T Cells. Immunity. 2016;44(3):712. https:\/\/doi.org\/10.1016\/j.immuni.2016.02.023.","journal-title":"Immunity"},{"issue":"95","key":"1416_CR59","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73. https:\/\/doi.org\/10.1126\/scitranslmed.3002842.","journal-title":"Sci Transl Med."},{"issue":"4","key":"1416_CR60","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4161\/onci.19855","volume":"1","author":"AA Hombach","year":"2012","unstructured":"Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology. 2012;1(4):458\u201366. https:\/\/doi.org\/10.4161\/onci.19855.","journal-title":"Oncoimmunology"},{"issue":"9","key":"1416_CR61","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1038\/s41375-019-0417-9","volume":"33","author":"MR Collinson-Pautz","year":"2019","unstructured":"Collinson-Pautz MR, Chang WC, Lu A, Khalil M, Crisostomo JW, Lin PY, et al. Constitutively active MyD88\/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies. Leukemia. 2019;33(9):2195\u2013207. https:\/\/doi.org\/10.1038\/s41375-019-0417-9.","journal-title":"Leukemia"},{"key":"1416_CR62","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96976","author":"S Guedan","year":"2018","unstructured":"Guedan S, Posey AD Jr, Shaw C, Wing A, Da T, Patel PR, et al. Enhancing CAR T cell persistence through ICOS and 4\u20131BB costimulation. JCI Insight. 2018. https:\/\/doi.org\/10.1172\/jci.insight.96976.","journal-title":"JCI Insight."},{"key":"1416_CR63","doi-asserted-by":"crossref","unstructured":"Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Molecular Therapy\u2014Nucleic Acids. 2013;2(7): 105.","DOI":"10.1038\/mtna.2013.32"},{"issue":"2","key":"1416_CR64","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/CJI.0b013e318194a6e8","volume":"32","author":"D Hollyman","year":"2009","unstructured":"Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 2009;32(2):169\u201380. https:\/\/doi.org\/10.1097\/CJI.0b013e318194a6e8.","journal-title":"J Immunother"},{"issue":"2","key":"1416_CR65","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/PPO.0000000000000036","volume":"20","author":"SR Riddell","year":"2014","unstructured":"Riddell SR, Sommermeyer D, Berger C, Liu LS, Balakrishnan A, Salter A, et al. Adoptive therapy with chimeric antigen receptor modified T cells of defined subset composition. Cancer journal (Sudbury, Mass). 2014;20(2):141.","journal-title":"Cancer journal (Sudbury, Mass)"},{"issue":"2","key":"1416_CR66","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","volume":"30","author":"D Sommermeyer","year":"2016","unstructured":"Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30(2):492\u2013500.","journal-title":"Leukemia"},{"issue":"9","key":"1416_CR67","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/CJI.0b013e31827806e6","volume":"35","author":"CA Klebanoff","year":"2012","unstructured":"Klebanoff CA, Gattinoni L, Restifo NP. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother. 2012;35(9):651\u201360. https:\/\/doi.org\/10.1097\/CJI.0b013e31827806e6.","journal-title":"J Immunother"},{"issue":"20","key":"1416_CR68","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","volume":"19","author":"LB John","year":"2013","unstructured":"John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19(20):5636\u201346.","journal-title":"Clin Cancer Res"},{"key":"1416_CR69","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv146","author":"S Kobold","year":"2015","unstructured":"Kobold S, Grassmann S, Chaloupka M, Lampert C, Wenk S, Kraus F, et al. Impact of a new fusion receptor on PD-1\u2013mediated immunosuppression in adoptive T cell therapy. J Natl Cancer Inst. 2015. https:\/\/doi.org\/10.1093\/jnci\/djv146.","journal-title":"J Natl Cancer Inst"},{"issue":"32","key":"1416_CR70","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","volume":"26","author":"ME Dudley","year":"2008","unstructured":"Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233\u20139.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1416_CR71","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12):1282\u201395.","journal-title":"Cancer Discov"},{"issue":"18","key":"1416_CR72","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","volume":"119","author":"HJ Pegram","year":"2012","unstructured":"Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012;119(18):4133\u201341.","journal-title":"Blood"},{"issue":"5","key":"1416_CR73","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, Wang X, S\u00e9n\u00e9chal B, Curran KJ, et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):449\u201359. https:\/\/doi.org\/10.1056\/NEJMoa1709919.","journal-title":"N Engl J Med"},{"issue":"6","key":"1416_CR74","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi L-A, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR\u2013T cells of defined CD4+: CD8+ composition in adult B cell ALL patients. J Clin Investig. 2016;126(6):2123.","journal-title":"J Clin Investig"},{"issue":"11","key":"1416_CR75","doi-asserted-by":"crossref","first-page":"e1027469","DOI":"10.1080\/2162402X.2015.1027469","volume":"4","author":"H Dai","year":"2015","unstructured":"Dai H, Zhang W, Li X, Han Q, Guo Y, Zhang Y, et al. Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology. 2015;4(11):e1027469.","journal-title":"Oncoimmunology"},{"issue":"18","key":"1416_CR76","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","volume":"75","author":"L Poirot","year":"2015","unstructured":"Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, Derniame S, et al. Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies. Can Res. 2015;75(18):3853\u201364.","journal-title":"Can Res"},{"issue":"2","key":"1416_CR77","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","volume":"45","author":"JC Fitzgerald","year":"2017","unstructured":"Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45(2):e124.","journal-title":"Crit Care Med"},{"issue":"1","key":"1416_CR78","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12185-016-2039-6","volume":"104","author":"ML Davila","year":"2016","unstructured":"Davila ML, Sadelain M. Biology and clinical application of CAR T cells for B cell malignancies. Int J Hematol. 2016;104(1):6\u201317.","journal-title":"Int J Hematol"},{"issue":"6","key":"1416_CR79","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739\u201348.","journal-title":"Nat Med"},{"key":"1416_CR80","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355.","journal-title":"Blood Rev"},{"issue":"6","key":"1416_CR81","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jgm.2604","volume":"14","author":"KJ Curran","year":"2012","unstructured":"Curran KJ, Pegram HJ, Brentjens RJ. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. The journal of gene medicine. 2012;14(6):405\u201315.","journal-title":"The journal of gene medicine"},{"issue":"23","key":"1416_CR82","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1182\/blood.V126.23.683.683","volume":"126","author":"SL Maude","year":"2015","unstructured":"Maude SL, Barrett DM, Ambrose DE, Rheingold SR, Aplenc R, Teachey DT, et al. Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed\/Refractory ALL. Blood. 2015;126(23):683\u2013683. https:\/\/doi.org\/10.1182\/blood.V126.23.683.683.","journal-title":"Blood"},{"issue":"1","key":"1416_CR83","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","volume":"1","author":"MV Maus","year":"2013","unstructured":"Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013;1(1):26\u201331.","journal-title":"Cancer Immunol Res"},{"issue":"17","key":"1416_CR84","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","volume":"75","author":"X Liu","year":"2015","unstructured":"Liu X, Jiang S, Fang C, Yang S, Olalere D, Pequignot EC, et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Can Res. 2015;75(17):3596\u2013607.","journal-title":"Can Res"},{"issue":"6","key":"1416_CR85","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","volume":"76","author":"X Liu","year":"2016","unstructured":"Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Can Res. 2016;76(6):1578\u201390.","journal-title":"Can Res"},{"issue":"4","key":"1416_CR86","doi-asserted-by":"crossref","first-page":"E459","DOI":"10.1073\/pnas.1524155113","volume":"113","author":"DT Rodgers","year":"2016","unstructured":"Rodgers DT, Mazagova M, Hampton EN, Cao Y, Ramadoss NS, Hardy IR, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci. 2016;113(4):E459\u2013E468468.","journal-title":"Proc Natl Acad Sci"},{"key":"1416_CR87","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fphar.2014.00254","volume":"5","author":"BS Jones","year":"2014","unstructured":"Jones BS, Lamb LS, Goldman F, Di Stasi A. Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol. 2014;5:254. https:\/\/doi.org\/10.3389\/fphar.2014.00254.","journal-title":"Front Pharmacol"},{"issue":"13","key":"1416_CR88","doi-asserted-by":"publisher","first-page":"LB-187","DOI":"10.1158\/1538-7445.Am2017-lb-187","volume":"77","author":"YG Lee","year":"2017","unstructured":"Lee YG, Chu H, Low PS. Abstract LB-187: New methods for controlling CAR T cell-mediated cytokine storms. Can Res. 2017;77(13):LB-187. https:\/\/doi.org\/10.1158\/1538-7445.Am2017-lb-187.","journal-title":"Can Res"},{"key":"1416_CR89","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3389\/fimmu.2018.00273","volume":"9","author":"ME Iezzi","year":"2018","unstructured":"Iezzi ME, Policastro L, Werbajh S, Podhajcer O, Canziani GA. Single-domain antibodies and the promise of modular targeting in cancer imaging and treatment. Frontiers in immunology. 2018;9:273.","journal-title":"Frontiers in immunology"},{"issue":"4","key":"1416_CR90","first-page":"502","volume":"22","author":"A Rajabzadeh","year":"2021","unstructured":"Rajabzadeh A, Rahbarizadeh F, Ahmadvand D, Kabir SM, Hamidieh AA. A VHH-Based Anti-MUC1 Chimeric Antigen Receptor for Specific Retargeting of Human Primary T Cells to MUC1-Positive Cancer Cells. Cell journal. 2021;22(4):502.","journal-title":"Cell journal"},{"issue":"4","key":"1416_CR91","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s12185-012-1037-6","volume":"95","author":"S Khaleghi","year":"2012","unstructured":"Khaleghi S, Rahbarizadeh F, Ahmadvand D, Rasaee MJ, Pognonec P. A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells. Int J Hematol. 2012;95(4):434\u201344.","journal-title":"Int J Hematol"},{"issue":"2","key":"1416_CR92","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/hyb.2008.0079","volume":"28","author":"SHA Bakhtiari","year":"2009","unstructured":"Bakhtiari SHA, Rahbarizadeh F, Hasannia S, Ahmadvand D, Iri-Sofla FJ, Rasaee MJ. Anti-MUC1 nanobody can redirect T-body cytotoxic effector function. Hybridoma. 2009;28(2):85\u201392.","journal-title":"Hybridoma"},{"issue":"15","key":"1416_CR93","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s40265-018-0989-0","volume":"78","author":"S Duggan","year":"2018","unstructured":"Duggan S. Caplacizumab: First Global Approval. Drugs. 2018;78(15):1639\u201342. https:\/\/doi.org\/10.1007\/s40265-018-0989-0.","journal-title":"Drugs"},{"issue":"10","key":"1416_CR94","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1021\/acs.molpharmaceut.8b00584","volume":"15","author":"N An","year":"2018","unstructured":"An N, Hou YN, Zhang QX, Li T, Zhang QL, Fang C, et al. Anti-multiple myeloma activity of nanobody-based anti-CD38 chimeric antigen receptor T cells. Mol Pharm. 2018;15(10):4577\u201388.","journal-title":"Mol Pharm"},{"issue":"2","key":"1416_CR95","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3390\/ijms19020403","volume":"19","author":"S De Munter","year":"2018","unstructured":"De Munter S, Ingels J, Goetgeluk G, Bonte S, Pille M, Weening K, et al. Nanobody Based Dual Specific CARs. Int J Mol Sci. 2018;19(2):403. https:\/\/doi.org\/10.3390\/ijms19020403.","journal-title":"Int J Mol Sci."},{"issue":"13\u201314","key":"1416_CR96","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.drudis.2006.05.009","volume":"11","author":"JS Haurum","year":"2006","unstructured":"Haurum JS. Recombinant polyclonal antibodies: the next generation of antibody therapeutics? Drug Discovery Today. 2006;11(13\u201314):655\u201360.","journal-title":"Drug Discovery Today"},{"issue":"10","key":"1416_CR97","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.yexcr.2012.03.004","volume":"318","author":"FR Jamnani","year":"2012","unstructured":"Jamnani FR, Rahbarizadeh F, Shokrgozar MA, Ahmadvand D, Mahboudi F, Sharifzadeh Z. Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells. Exp Cell Res. 2012;318(10):1112\u201324.","journal-title":"Exp Cell Res"},{"issue":"24","key":"1416_CR98","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci. 1989;86(24):10024\u20138.","journal-title":"Proc Natl Acad Sci"},{"issue":"18","key":"1416_CR99","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","volume":"13","author":"RJ Brentjens","year":"2007","unstructured":"Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13(18):5426\u201335.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1416_CR100","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/onci.19855","volume":"1","author":"AA Hombach","year":"2012","unstructured":"Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells. Oncoimmunology. 2012;1(4):458\u201366.","journal-title":"Oncoimmunology"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-020-01416-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-020-01416-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-020-01416-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T06:15:08Z","timestamp":1744179308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-020-01416-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":100,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1416"],"URL":"https:\/\/doi.org\/10.1007\/s12032-020-01416-3","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,12]]},"assertion":[{"value":"28 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"100"}}